Biomarkers In Gynecological Malignancies: From Multi-Omics Discovery to Machine Learning-Driven Precision Care
Gynecological malignancies, including ovarian, endometrial, and cervical cancers, pose a significant global health burden, with high mortality rates and limited treatment options. Biomarkers and machine learning can improve cancer care by enabling early detection, accurate risk stratification, and individualized treatment selection.
Gynecological cancers, such as ovarian, endometrial, and cervical cancers, affect women worldwide, with high mortality rates. Biomarkers can help improve cancer care. Advances in genomics and machine learning enable biomarker discovery and integration of complex datasets. This can lead to precision screening, early detection, and therapy selection. Researchers are working to bridge discovery science with clinical application. The goal is to improve outcomes in gynecological cancers through innovative research and clinical trials.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.